Acetylcholinesterase inhibitors for schizophrenia

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2009, Pages

  Singh, Jasvinder ^a   Kour, Kamalpreet ^b   Jayaram, Mahesh B ^b  

^a Lynfield Mount Hospital   (United Kingdom)

^b LEEDS AND YORK PARTNERSHIP NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; PLACEBO;

HUMAN; OUTCOME ASSESSMENT; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 70049102737     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007967     Document Type: Review

References (26)

1. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200.
2. Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
3. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, Boutitie F, Nony P, Haugh M, Mignot G. The problemof therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie 1999;54(4):405-411 (Pubitemid 29476240)
4. Carpenter WT Jr, Buchanan RW. Schizophrenia. New England Journal of Medicine 1994;10(330):681-690
5. Deeks JJ. Issues in the selection of a summary statistic for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town, South Africa. Cape Town: Cochrane Collaboration, 2000.
6. Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623-629
7. Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-2980
8. Egger M, Davey-Smith G, Schneider M, Minder CSO. Bias in metaanalysis detected by a simple, graphical test. BMJ 1997;13:629-634 (Pubitemid 27387172)
9. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-149 (Pubitemid 34284916)
10. Gelenberg AJ, Levy P, Manoukian SV. Maintaining metabolic and cardiovascular health in patients with schizophrenia: perspectives in long-term care. http://cme.medscape.com/viewarticle/491506 (accessed 08 May 2009).
11. Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-883
12. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560
13. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochranehandbook. org.
14. Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, Day R, Bertelsen A. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization tencountry study. Psychological Medicine. Monograph Supplement 1992; 20:1-97.
15. Kay SR, Opler LA, Fiszbein A. Positive and negative syndrome scale (PANSS) manual. Schizophrenia Bulletin 1987;13(2):261-276
16. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2-3): 231-238
17. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-252 (Pubitemid 30179844)
18. Mueser KT, McGurkn SR. Schizophrenia. The Lancet 2004;363 (9426):2063-2072
19. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799-812
20. Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dubé S, Mallinckrodt C, Bymaster FP, McKinzie DL, Felder CC. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. American Journal of Psychiatry 2008;165:1033-1039
21. Stephen M Stahl. Psychopharmacology of reward and drugs of abuse. Essential psychopharmacology. 2nd Edition. Cambridge University Press, 2000:469-470
22. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review.. Health Technology Assessment 1999;3(5): (Pubitemid 29201269)
23. Winkler J, Thal LJ, Gage FH, Fisher LJ. Cholinergic strategies for alzheimer's disease. Journal of Molecular Medicine 1998;76:555-567
24. Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, Chang Z, Woolsey J. Drug Bank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Research 2006; 34:D668-72.
25. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, Pinfold V, Takriti Y. The Leeds Outcomes Stakeholders Survey (LOSS) Study. Proceedings of the 15th Cochrane Colloquium; 2007 Oct 23-27; Sao Paulo. 2007.
26. Yeomans JS. Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia. Neuropsychopharmacology 1995;12(1):3-16.